相似文献
1
Promising Molecular Therapeutic Targets for Drug Development in Rheumatoid Arthritis.类风湿关节炎药物研发中颇具前景的分子治疗靶点
J Clin Med. 2025 Aug 18;14(16):5827. doi: 10.3390/jcm14165827.
2
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
5
DS-Modified Paeoniflorin pH-Responsive Lipid-Polymer Hybrid Nanoparticles for Targeted Macrophage Polarization in a Rat Model of Rheumatoid Arthritis.用于类风湿性关节炎大鼠模型中靶向巨噬细胞极化的DS修饰芍药苷pH响应性脂质-聚合物杂化纳米颗粒
Int J Nanomedicine. 2025 Jul 12;20:8967-8992. doi: 10.2147/IJN.S516434. eCollection 2025.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
7
Relationship Between Pituitary Gland and Stem Cell in the Aspect of Hormone Production and Disease Prevention: A Narrative Review.垂体与干细胞在激素产生和疾病预防方面的关系：一篇叙述性综述
Endocr Metab Immune Disord Drug Targets. 2025 Jan 13. doi: 10.2174/0118715303314551241031093717.
8
Identification of novel, clinically correlated autoantigens in the monogenic autoimmune syndrome APS1 by proteome-wide PhIP-Seq.通过全蛋白质组 PhIP-Seq 鉴定单基因自身免疫综合征 APS1 中的新型临床相关自身抗原。
Elife. 2020 May 15;9:e55053. doi: 10.7554/eLife.55053.
9
Type 1 Diabetes: A Guide to Autoimmune Mechanisms for Clinicians.1型糖尿病：临床医生自身免疫机制指南
Diabetes Obes Metab. 2025 May 15. doi: 10.1111/dom.16460.
10
Methotrexate, blood pressure and arterial function in rheumatoid arthritis: study protocol.甲氨蝶呤、类风湿关节炎患者的血压和动脉功能：研究方案。
Future Cardiol. 2024;20(13):671-683. doi: 10.1080/14796678.2024.2411167. Epub 2024 Oct 10.
本文引用的文献
1
Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry.类风湿关节炎患者对JAK抑制剂反应不足时，从JAK抑制剂间循环用药转换为使用生物改善病情抗风湿药：来自FIRST注册研究
RMD Open. 2025 Jan 21;11(1):e004987. doi: 10.1136/rmdopen-2024-004987.
2
Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.泰吉华单抗：靶向自身免疫和风湿性疾病的新突破。
J Autoimmun. 2024 Sep;148:103291. doi: 10.1016/j.jaut.2024.103291. Epub 2024 Aug 14.
3
The SMILE study: Study of long-term methotrexate and iguratimod combination therapy in early rheumatoid arthritis.SMILE研究：甲氨蝶呤与艾拉莫德联合长期治疗早期类风湿关节炎的研究。
Chin Med J (Engl). 2024 Jul 26. doi: 10.1097/CM9.0000000000003200.
4
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis.OX40抑制剂替雷佐利单抗治疗中度至重度特应性皮炎的2b期随机试验。
J Allergy Clin Immunol Glob. 2023 Nov 22;3(1):100195. doi: 10.1016/j.jacig.2023.100195. eCollection 2024 Feb.
5
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis.罗卡替尼单抗治疗中度至重度特应性皮炎的疗效。
Lancet. 2023 Nov 18;402(10415):1833-1834. doi: 10.1016/S0140-6736(23)01619-7.
6
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).抗 GM-CSF 奥替利珠单抗对比托法替布或安慰剂用于常规治疗或生物制剂 DMARDs 应答不足的活动性类风湿关节炎患者：两项 3 期随机试验（contRAst 1 和 contRAst 2）。
Ann Rheum Dis. 2023 Dec;82(12):1516-1526. doi: 10.1136/ard-2023-224482. Epub 2023 Sep 12.
7
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial.奥昔利单抗（一种完全人源、非耗竭性、非细胞毒性的 OX40 配体单克隆抗体）治疗特应性皮炎的安全性和有效性：一项 IIa 期随机安慰剂对照试验的结果。
Br J Dermatol. 2023 Oct 25;189(5):531-539. doi: 10.1093/bjd/ljad240.
8
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis.佩雷索利单抗治疗成人类风湿关节炎的 2 期临床试验。
N Engl J Med. 2023 May 18;388(20):1853-1862. doi: 10.1056/NEJMoa2209856.
9
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.抗 OX40 抗体治疗中重度特应性皮炎：一项多中心、双盲、安慰剂对照的 2b 期研究。
Lancet. 2023 Jan 21;401(10372):204-214. doi: 10.1016/S0140-6736(22)02037-2. Epub 2022 Dec 9.
10
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.EULAR 推荐的类风湿关节炎治疗方案：使用合成和生物疾病修正抗风湿药物：2022 更新版。
Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10.
Zotero 插件